Literature DB >> 9728542

Borreliacidal antibody production against outer surface protein C of Borrelia burgdorferi.

J C Rousselle1, S M Callister, R F Schell, S D Lovrich, D A Jobe, J A Marks, C A Wieneke.   

Abstract

Early Lyme borreliosis sera with significant titers of anti-outer surface protein C (OspC) borreliacidal antibodies were identified. Human anti-OspC borreliacidal antibodies could be either IgM or IgG. Significant concentrations of borreliacidal activity were detected after vaccination of mice with OspC. Detection of anti-OspC borreliacidal activity was dependent on surface expression of OspC by Borrelia burgdorferi isolate 50772. The ability of OspC to induce borreliacidal antibodies in vivo and after vaccination offers another possible explanation for the ability of vaccination with OspC to protect against infection with B. burgdorferi. Furthermore, detection of anti-OspC borreliacidal antibodies, especially IgM antibodies, in early Lyme borreliosis sera provides additional evidence that borreliacidal antibody detection may be useful for the serodiagnosis of early Lyme borreliosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9728542     DOI: 10.1086/515382

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  29 in total

1.  Detection of borreliacidal antibodies in Lyme borreliosis patient sera containing antimicrobial agents.

Authors:  D A Jobe; N Rawal; R F Schell; S M Callister
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

Review 2.  The emergence of Lyme disease.

Authors:  Allen C Steere; Jenifer Coburn; Lisa Glickstein
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 3.  Diversity of the Lyme Disease Spirochetes and its Influence on Immune Responses to Infection and Vaccination.

Authors:  Jerilyn R Izac; Richard T Marconi
Journal:  Vet Clin North Am Small Anim Pract       Date:  2019-04-06       Impact factor: 2.093

4.  Construction and analysis of variants of a polyvalent Lyme disease vaccine: approaches for improving the immune response to chimeric vaccinogens.

Authors:  Christopher G Earnhart; Richard T Marconi
Journal:  Vaccine       Date:  2007-01-17       Impact factor: 3.641

5.  Analysis of antibody response in humans to the type A OspC loop 5 domain and assessment of the potential utility of the loop 5 epitope in Lyme disease vaccine development.

Authors:  Eric L Buckles; Christopher G Earnhart; Richard T Marconi
Journal:  Clin Vaccine Immunol       Date:  2006-10

6.  Production of borreliacidal antibody to outer surface protein A in vitro and modulation by interleukin-4.

Authors:  E L Munson; B K Du Chateau; D A Jobe; S D Lovrich; S M Callister; R F Schell
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

7.  Analysis of the antigenic determinants of the OspC protein of the Lyme disease spirochetes: Evidence that the C10 motif is not immunodominant or required to elicit bactericidal antibody responses.

Authors:  Jerilyn R Izac; Andrew C Camire; Christopher G Earnhart; Monica E Embers; Rebecca A Funk; Edward B Breitschwerdt; Richard T Marconi
Journal:  Vaccine       Date:  2019-03-25       Impact factor: 3.641

8.  Gamma interferon inhibits production of Anti-OspA borreliacidal antibody in vitro.

Authors:  Erik L Munson; Brian K Du Chateau; Jani R Jensen; Steven M Callister; David J DeCoster; Ronald F Schell
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

9.  Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease.

Authors:  Rhonda L LaFleur; Jennifer C Dant; Terri L Wasmoen; Steven M Callister; Dean A Jobe; Steven D Lovrich; Thomas F Warner; O Abdelmagid; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2008-12-03

10.  C-terminal region of outer surface protein C binds borreliacidal antibodies in sera from patients with Lyme disease.

Authors:  Dean A Jobe; Steven D Lovrich; Ronald F Schell; Steven M Callister
Journal:  Clin Diagn Lab Immunol       Date:  2003-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.